These antibodies have been shown to improve anti-tumor T cell responses in preclinical and early clinical studies (reviewed in [12]) and can enhance the efficacy of α-PD-1 and α-CTLA-4 therapy (e.g., [13, 14]). Here, CTLA4 is linked to neoplasm.